Date: Nov. 29, 2021

Source: Biomedical Translational Research Institute

JNU and the G.D. Kongming Therapeutics Co., Ltd., signed a transfer agreement Nov. 25 for allogeneic Vγ9Vδ2-T cCell immune therapy, a scientific achievement by Prof. Yin Zhinan's team from JNU's Biomedical Translational Research Institute.

(Signing the agreement)

The therapy represents new hope for patients with tumors, especially advanced solid tumors. Without genetic engineering transformation, allogeneic Vγ9Vδ2-T cells  by nature have only mild side effects during treatment and are therefore effective at relatively low cost. This transfer is JNU's latest achievement in accelerating the transformation of scientific and technological achievements and creating a new mode of industry-university-research cooperation.

Under the leadership of Yin, the company's founder and chief scientist, its technical team has made a series of achievements on Vγ9Vδ2-T that have been published in high-level international academic journals. At the same time, the team has applied for Chinese and international patents for its core technologies. At present, the team is collaborating with top tertiary hospitals in Guangzhou, Shenzhen, Zhuhai, Wuhan and Shanghai, doing clinical research on Vγ9Vδ2-T cells in the treatment of malignant tumors, and helping formulate industry standards. The team has become an international leader in allogeneic cell immunotherapy.